Human chorionic gonadotropin adjuvant therapy for patients with Leydig cell dysfunction after varicocelectomy

Area of Science:

• Reproductive Endocrinology
• Andrology
• Urology

Background:

• Varicocelectomy is a common procedure for male infertility.
• Persistent Leydig cell dysfunction can occur post-varicocelectomy, impacting testosterone production and sperm quality.
• Luteinizing hormone-releasing hormone (LHRH) testing can identify subtle Leydig cell dysfunction.

Purpose of the Study:

• To evaluate the efficacy of human chorionic gonadotropin (hCG) in treating Leydig cell dysfunction after varicocelectomy.
• To assess the impact of hCG on sperm parameters, serum hormone levels, and pregnancy rates.
• To determine if hCG can stimulate intratesticular testosterone production in affected patients.

Main Methods:

• A cohort of 135 men with post-varicocelectomy Leydig cell dysfunction received intramuscular hCG (50,000 units over 10 weeks).
• Semen analysis and serum hormone levels were measured at baseline and follow-up intervals (8 weeks post-treatment, then every 3 months).
• Patients were followed for 2 years to confirm pregnancy outcomes.

Main Results:

• Fifty-five percent of treated patients achieved pregnancy.
• Significant improvements were observed in sperm density, motility, normal morphology, and serum testosterone levels.
• hCG administration effectively stimulated intratesticular testosterone production.

Conclusions:

• hCG is a recommended treatment for men with persistent Leydig cell dysfunction following varicocelectomy.
• hCG therapy can enhance fertility by improving sperm parameters and restoring testosterone levels.
• This treatment approach offers a viable option for stimulating testosterone production and improving reproductive outcomes.